Business
AstraZeneca to run fresh COVID-19 vaccine trial amid results confusion – The Australian Financial Review
AstraZeneca and its CEO are facing scrutiny as the drugmaker responds to growing confusion over the vaccine.
AstraZeneca and its partner, the University of Oxford, reported on Monday that a lower initial dose of the vaccine, followed by a full dose, produced a 90 per cent efficacy rate, compared with 62 per cent for two full doses.
A day after the data were unveiled the head of the US vaccine program known as Operation Warp Speed said that the regimen showing the higher level of effectiveness was tested in a younger population. He also said that the half-dose was given to some people because of an error…
-
Noosa News19 hours agoHow errors, penalties and bad decisions helped New South Wales beat themselves in Origin II
-
Business12 hours agoWhy this speculative ASX stock could rise 100%+
-
General19 hours agoActivism under the guise of good intentions
-
General19 hours agoSeeking a reset on the environment debate, Murray Watt gathers business and conservation groups in search of a deal